PharmaFocus Today – Page 50 – media

Domestic endoscopy giant acquires European counterparts

On September 18, Micro-Tech (NL) International B.V. announced that the company intends to use its own funds of no more than 36.72 million euros (equivalent to approximately 289 million yuan) to purchase 51% of the shares of Creo Medical S.L.U. (hereinafter referred to as “CME”) held by CreoMedical Group plc (hereinafter referred to as “Creo”) through its wholly-owned subsidiary Micro-Tech (NL) International B.V. After the completion of this transaction, CME will become a holding subsidiary of the company. The announcement shows that Creo is a medical device company headquartered in the UK and listed on the London Stock Exchange (stock code: CREO). Creo focuses on the development and commercialization of minimally invasive surgical equipment in the field of surgical endoscopy. Its main product is CROMA, an electrosurgical platform that can provide microwaves and bipolar radiofrequency for local cutting through a single accessory port, providing doctors with simplified and controllable surgical ...
- Source: drugdu
- 119
- September 24, 2024
The chairman of Sinopharm Holdings has been replaced, and he comes from China Resources Group

Recently, Sinopharm Holdings issued an announcement on changes in the composition of the board committee, and Zhao Bingxiang was appointed as a non-executive director of Sinopharm. According to the process at the end of August, “the board of directors of Sinopharm has decided to elect Zhao Bingxiang as chairman of the board of directors. This appointment must be approved by shareholders at the shareholders’ meeting before the appointment of its non-executive director can take effect.” Zhao Bingxiang’s appointment as a non-executive director of Sinopharm also means that His appointment as chairman of the state-controlled company takes effect. At present, Sinopharm’s official website and announcement information have been updated, and Zhao Bingxiang serves as the chairman, non-executive director and party committee secretary of Sinopharm Holdings. It is reported that Zhao Bingxiang has worked in the China Resources department for a long time. He has served as a senior researcher at the ...
- Source: drugdu
- 72
- September 24, 2024
Yingsi Intelligent’s world’s first TNIK inhibitor ISM001-055 has achieved positive results in phase IIa clinical trials

·ISM001-055 is an innovative drug driven by generative artificial intelligence and fully developed independently by Insilicon Intelligence. It targets TNIK (Traf2/NCK interacting kinase) and has completed phase IIa clinical trials for the treatment of patients with idiopathic pulmonary fibrosis (IPF); ·This study lasted for 12 weeks, and its preliminary results showed that ISM001-055 exhibited good safety in IPF patients and showed a dose-dependent pharmacological trend in improving lung function indicators in patients; ·The positive clinical trial results of ISM001-055 also provide the first conceptual validation for AI driven drug development. Hong Kong, China, September 18, 2024- Yingsi Intelligent, a clinical stage biotechnology company driven by generative artificial intelligence (AI), announced that its pipeline ISM001-055 has achieved positive preliminary research results in a phase IIa clinical trial. ISM001-055 is a “first in class” small molecule inhibitor driven by generative AI for drug discovery and design, targeting TNIK (Traf2/NCK interacting kinase) for ...
- Source: drugdu
- 103
- September 23, 2024
Yuheng Biotechnology announces the release of APHEXDA (Antifotide) ®, Motixafortide has been approved for marketing by the Macau Drug Administration in China

Motefutide Macau officially approvedOn September 20, 2024, Guangzhou Yuheng Biotechnology Co., Ltd. (referred to as “Yuheng Biotechnology”) announced the world’s first peptide drug, Mortifutide (APHEXDA), targeting the chemokine receptor 4 (CXC chemokine receptor 4, CXCR4) ®， Motixafortide has recently been officially approved for marketing by the Drug Administration of the Macao Special Administrative Region of China. According to the WHO ATC (Anatomical Therapeutic Chemical Classification System) drug classification management system, it has been approved as immune enhancer L03AX23, which is used in combination with granulocyte colony-stimulating factor (G-CSF) to mobilize hematopoietic stem cells for peripheral blood stem cell collection and subsequent autologous transplantation in patients with multiple myeloma (MM). After Boao, Hainan, Macau has become the second region within Yuheng Biotech’s Asia authorized area to receive approval for Motefutide. Motefutide has obtained new drug approval in the United States in September 2023. It is the first approved innovative drug for ...
- Source: drugdu
- 209
- September 23, 2024
Lepu Biotech’s Injection of Vebecotamab Aiming for Priority Review for Nasopharyngeal Carcinoma

On September 19, the National Medical Products Administration (NMPA) released a public notice on its drug evaluation center’s official website, announcing that Lepu Biotech’s injection of Vebecotamab is proposed for priority review. This treatment is intended for patients with recurrent or metastatic nasopharyngeal carcinoma who have previously failed at least two lines of systemic chemotherapy and PD-1/PD-L1 inhibitor therapies. This drug, developed by Lepu Biotech, is an antibody-drug conjugate (ADC) targeting EGFR, with the development code MRG003. It is composed of an EGFR-targeted monoclonal antibody linked to a potent microtubule inhibitor, MMAE, through a vc linker. The molecular design of this drug has the potential to extend its application to a broader range of cancers that overexpress EGFR and may overcome various types of resistance caused by common mutations. In its previously published semi-annual report, Lepu Biotech indicated plans to submit a new drug application (NDA) for MRG003 to the ...
- Source: drugdu
- 101
- September 23, 2024
AstraZeneca’s “Class 1 Anti-heart Failure Chemical Drug” has applied for clinical trials in China

On September 14, according to the official website of CDE, AstraZeneca’s clinical trial application for the Class 1.1 chemical drug AZD5462 tablets was accepted. According to public information, the drug is a relaxin RXFP1 receptor agonist. Relaxin, as an agonist of the relaxin 1 receptor (RXFP1), produces unique and diverse biological effects, including pulmonary and systemic vasodilation, tissue remodeling/fibrosis reversal, and reduced inflammation, and therefore also has potential in cardiopulmonary diseases. significant curative effect. In addition, this substance is also known as the “pregnancy hormone” and is regulated during pregnancy to help the expectant mother’s cardiovascular system meet the increased demands of the developing fetus and remodel tissue and musculoskeletal structure. . AZD5462 is a relaxin RXFP1 receptor agonist developed by AstraZeneca. Preclinical studies on monkey models of heart failure with reduced ejection fraction (HFrEF) showed that cardiac systolic function was improved after 8 weeks of treatment. There was no ...
- Source: drugdu
- 103
- September 23, 2024
Countdown to the National Hospital Inspection

Recently, the State Council Information Office held a series of themed press conferences on “Promoting High-quality Development”. Yan Qinghui, deputy director of the National Medical Insurance Administration, said that so far, a total of 432 designated medical institutions in 30 provinces have been inspected. It is expected that the number of inspected institutions this year will exceed the total of the past five years, and the expansion is relatively large. According to incomplete statistics from Cyber Blue, as of September 18, the national flight inspection team has landed in Hebei, Shanxi, Liaoning, Jilin, Heilongjiang, Jiangsu, Zhejiang, Anhui, Fujian, Shandong, Henan, Hubei, Hunan, Guangdong, Hainan, Sichuan, Guizhou, Yunnan, Shaanxi, Gansu, Qinghai, Inner Mongolia, Guangxi, Tibet, Ningxia, Xinjiang, Beijing, Shanghai and other places (see the attachment at the end of the article for details). According to the work arrangements of the National Medical Insurance Administration, all provinces across the country will complete ...
- Source: drugdu
- 106
- September 23, 2024
Breaking the domestic gap! New Pulse Medical opens a new era in the TAVR market

Domestic companies have created a new situation in the TAVR market and created a new market engine. On August 14, 2024, the State Food and Drug Administration officially approved the domestic Prizvalve transcatheter aortic valve system developed by New Pulse Medical. As the first self-developed balloon-expandable valve launched in China, the Prizvalve valve system is expected to be the first to break the import monopoly, effectively improve the quality of life, and quickly capture market share. Aortic valve disease mainly includes aortic valve stenosis and aortic valve regurgitation. With the deepening of aging, the prevalence of cardiovascular diseases (including aortic valve stenosis) continues to rise, and the number of patients with aortic valve disease in the world and China has increased year by year. This change has not only had a serious impact on the quality of life of patients, but also posed severe challenges to the medical system. Traditional ...
- Source: drugdu
- 66
- September 23, 2024
the dawn of treatment for multiple myeloma!

Original Medical Overview Medical Overview September 19, 2024 08:54 Shanghai Multiple myeloma (MM) is a blood cancer that, despite advances in treatment methods in recent years, remains an incurable disease. The traditional treatment options for MM include the combination of proteasome inhibitors (PIs), immunomodulators (IMiDs), and monoclonal antibodies (Mo Abs). Although these methods improve patient survival and progression free survival (PFS), with the emergence of treatment resistant clones, patients will eventually develop resistance to these treatments. Therefore, researchers are exploring new treatment strategies such as CAR-T cell therapy and bispecific antibodies, which activate immune T cells to kill tumor cells. Based on the review of bispecific antibodies and multiple myeloma published in the Blood Cancer Journal this month, let’s talk about the design, mechanism of action, current clinical trials, and future development directions of bispecific antibodies. 01 Bispecific antibodies and therapeutic targets Bispecific antibodies (BsAbs) are antibody constructs with two ...
- Source: drugdu
- 120
- September 21, 2024
Nat Microbiol | Liu Wei/Li Hao reveal new mechanism of bile acid protection against SFTSV (fever with thrombocytopenia syndrome) infection

BioArt September 19, 2024 08:45 Shanghai Bile acids are metabolites produced by the synergistic effect between the host and its gut microbiota. They can regulate various biological functions and affect the host’s susceptibility to viral infections, especially enteroviruses and hepatitis viruses, by activating specific receptors and cellular signaling pathways in intestinal and liver tissues. A small fraction (<10%) of total bile acids can enter the systemic circulation and may play a critical role in antiviral immunity during systemic infections. However, the function and mechanism of bile acids in regulating the host’s immune response to viral systemic infections are still poorly understood, and the association between bile acid metabolism and disease outcomes of viral systemic infections is also unclear. Viral hemorrhagic fever is usually caused by highly pathogenic RNA viruses, which can lead to severe systemic infections, multiple organ failure, and even death. Severe fever with thrombocytopenia syndrome (SFTS) is a ...
- Source: drugdu
- 100
- September 21, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.